posted
Alert Look this ---****************: Issues Updates on Xechem International Incorporated
Mar 15, 2006 (M2 PRESSWIRE via COMTEX) -- Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the OTC exchange has brought Xechem International Incorporated (OTCBB:XKEM) to the attention of our research team. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. Shares of Xechem International Incorporated slipped 5% today to $.016 while trading 22 million at the time of publication. Although the company has not released any press today, the recent activity could be a carry over from yesterday's news. Xechem International announced yesterday that it has submitted its Orphan Drug Application for the five-membered heterocyclic anti-sickling compound known as 5-HMF to the United States Food and Drug Administration (FDA).
As reported on December 9, 2005, this promising compound has shown excellent biological activity in preliminary testing as an anti-sickling agent. This was discovered by Prof. Donald Abraham and his team of scientists from Virginia Commonwealth University (VCU), Richmond, VA in collaboration with a team of doctors and scientists at NHLBI Sickle Cell Disease Reference Laboratory at The Children's Hospital of Philadelphia (CHOP), University of Pennsylvania led by Professor Toshio Asakura. Xechem has acquired the exclusive, worldwide rights from VCU for the production, sales and marketing of 5-HMF for use in the battle against SCD.
Research has shown that the 5-HMF compound is not only a natural product with very little if any toxicity, it also appears to be an effective anti-sickling agent which has shown high affinity for hemoglobin and is very active in genetically modified transgenic (Tg) mice. Professor Abraham of VCU has characterized this compound as "the best potential antisickling agent in 30 years research to be discovered by (VCU's) research group." See Xechem's December 9, 2005 Press Release.
If granted, Orphan Drug status will afford Xechem seven years of marketing exclusivity for the drug once the drug is ultimately approved by the FDA, and will offer Xechem tax credits, filing fee waivers and certain other statutory benefits.
According to Xechem's Chairman and CEO, Dr. Ramesh C. Pandey, "This new compound licensed from VCU represents the latest effort undertaken by Xechem in the fight against Sickle Cell Disease (SCD), and adds to Xechem's existing arsenal of NICOSAN(TM)/HEMOXIN(TM), an all natural, phyto-pharmaceutical product that has shown enormous promise for SCD sufferers. NICOSAN(TM)/HEMOXIN(TM) has already been designated as an Orphan Drug both in the United States and in European Union countries. It was acquired under an exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Government of Nigeria, Between the progress we have been making in bringing NICOSAN(TM) to market, and this exciting new heterocyclic pharmaceutical agent being developed in collaboration with VCU, we expect Xechem to be front and center in eventually offering the most viable and efficacious treatments to patients suffering with SCD around the world." Dr. Pandey added that the Company intends shortly to prepare and file an Investigational New Drug (IND) Application for submission to the FDA for both HEMOXIN(TM) and 5-HMF.
To view other Market Gainer reports in this and other sectors, please visit www.**************** for a complimentary subscription to the newest and most exciting online financial newsletter on the market. This article is available for viewing in the featured articles section on our website. No Credit Card information needed.
New to the Market Gainer's website is our very own in-site blog, offering our subscribers the opportunity to communicate with fellow investors without all the spam found in other investment blogs. Click on talking stocks after you subscribe to join, and enhance your investment knowledge and community.
The Financial Information and Financial Content provided by **************** is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by ****************. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by **************** to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. **************** does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.
All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info*m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
-0-
Search for Dun & Bradstreet reports on this company.
-------------------- "Many of life's failures are people who did not realize how close they were to success when they gave up." -
posted
added 200k yesterday * .016 will add more if it drops below .015. I'm calling this averaging down, not catching a falling knife. We'll see if I'm right. anyone else adding?
IP: Logged |
posted
Anybody have any target prices on this? I got a few shares of this a while ago at .0146 and held onto it during the last rally thinking it would easily crest 0.35 when it lost steam at about .027. Still think it's a good buy with a high flip potential, esp. with all the PRs on the horizon, but the MMs are really playing with this
IP: Logged |
posted
Does anybody (besides me) have shares of FMLY and XKEM. It's remarkable how they both move. When one moves (up or down), the other one has a similar pattern a couple of days later. Eventually things settle and they end up at the same price.
IP: Logged |
posted
bilgert: Thought about getting FMLY awhile back, but went with USXP instead. It's pattern is similar as well, although it is retreating further than XKEM this time around. I'm watching both for now and plan to pick one of them up shortly.
posted
Just spoke with IR for XKEM...They could get ok for drug in Nigeria ANY DAY now, and with OTHER COUNTRIES to follow..This is what I thought, but was nice to confirm it...Takes longer in the US, however, once working in other countries, that could speed up process here
IP: Logged |
quote:Originally posted by redgurl19: XKEM GAPPER TOMMOROW
yea, just like today, yesterday and every other day. We need some news for a gapper. I picked up another 40,000 today hoping it flies soon. I got rid of my PAIM to buy this. This stands a better chance of coming through first.
-------------------- corn oil comes from corn, olive oil from olives, where does baby oil come from?
IP: Logged |
posted
XKEM from other board (in addition to myself talking to Stephen Burg today):
NIZ,The Govt Is Under Alot Of Pressure To Get The Drug Approved ASAP. I Talked To Steve Today And He Said The Factory Is Built And All The Supplies And Personel Are Ready To Go And That Revs Start From Day 1. All We Need Is That Green Light. The Nigerian Govt Will Pay For The Drug And Distribute It. We Are Babies Breath Away.
posted
from ragingbull--- a lot of people call to IR of XKEm .---- By: machcobra 17 Mar 2006, 04:24 PM EST Msg. 15894 of 15903 (This msg. is a reply to 15890 by mpd68.) Jump to msg. # mpd, Steve told me as well all done except a couple pieces of equipment, which is really no big deal. You can be certain we will be hearing as soon as the approval comes and by the way Steve talks could be any minute. You know how that goes... - - - - - View Replies »
Advertisements • Low Rate Source: $200k for $643/
-------------------- "Many of life's failures are people who did not realize how close they were to success when they gave up." -
posted
By: backdoorbear 17 Mar 2006, 04:55 PM EST Msg. 15904 of 15904 (This msg. is a reply to 15890 by mpd68.) Jump to msg. # mpd68
I can't recall his precise words, but Steve indicated that construction of the production facility has been ongoing for some time, that it is almost finished, and all that remains is to add a few items of equipment. My impression was that the key event will be the final approval of HEMOXIN, and that the facility should be ready for porduction at that time.
Advertisements
-------------------- "Many of life's failures are people who did not realize how close they were to success when they gave up." -
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
